Key result
First-in-human clinical experience with the self-expandable Edwards CENTERA transcatheter heart valve has been promising, though larger series with longer follow-up are warranted.
The Edwards CENTERA transcatheter heart valve features a motorized delivery system that potentially allows for accurate placement and repositioning by a single operator.
Answers are grounded in this paper and cite their sources.
Early CENTERA experience is hypothesis-generating; does not yet support changes in clinical practice.
Transcatheter aortic valve implantation (TAVI) has been adopted worldwide as a prominent therapeutic alternative for patients with high-risk severe symptomatic aortic stenosis. Despite its more widespread adoption as a treatment option and the increasing experience of the centres, TAVI is still associated with complications. Therefore, improvements in transcatheter heart valve (THV) technology, such as optimisation of device function with superior deliverability, and valve repositioning, are desirable. Accordingly, this article describes the new self-expandable Edwards CENTERA THV, made of nitinol and treated bovine pericardial tissue, and delivered by a motorised low-profile delivery system which potentially permits accurate valve placement and valve repositioning by a single operator. First-in-human clinical experience with the CENTERA THV has been promising but larger series with longer follow-up are warranted to confirm these initial positive results.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2012) conducted a review in high-risk severe symptomatic aortic stenosis. Edwards CENTERA THV was evaluated. First-in-human clinical experience with the self-expandable Edwards CENTERA transcatheter heart valve has been promising, though larger series with longer follow-up are warranted.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: